Press releases

Genoskin is proud to announce the publication of a groundbreaking scientific article in Science Advances, introducing a new analytic pipeline called MANTIS^® (Multiplexed Annotated Tissue Imaging System). The article, authored by a team of eighteen researchers, outlines MANTIS’s ability to solve the spatial organization of complex immune environments in experimental or clinical skin samples.

Genoskin, a leading Franco-American TechBio company specializing in bio-stabilized immunocompetent human skin platforms, and PharmaJet, an innovative provider of Precision Delivery Systems (PDS), announce a strategic research partnership during the World Vaccine Congress. The collaboration aims to explore the advantages of PharmaJet’s Intradermal PDS focusing on how it can enable vaccine delivery to human skin. Genoskin’s innovative ex-vivo platform will further enable the characterization of PharmaJet’s PDS on the skin’s immune profile.

Genoskin is thrilled to welcome Dr. Florent Ginhoux, PhD, to its Scientific Advisory Board (SAB). After last year’s nomination of world-renowned immunology expert, Dr. Nicolas Gaudenzio, as Genoskin’s CSO, Dr. Ginhoux will now bring his world-class expertise as Highly Cited Researcher in tissue-resident immune cell biology and associated pathophysiological responses to the table.

Genoskin launches MANTIS^®, a spatial biology imaging platform dedicated to skin immunology. The MANTIS^® (Multiplex ANnotated Tissue Imaging System) platform was developed at Infinity (Inserm U1291, France) by a team of experts under the guidance of Dr. Nicolas Gaudenzio, who was recently appointed as our Chief Scientific Officer (CSO).

Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of a research group at the Infinity Institute (Toulouse Institute for Infectious and Inflammatory Diseases, France), which focuses on the neuronal regulation of immune response.

Genoskin announces the launch of the ISR platform^®, a new pre-clinical toolbox designed to study injection site reactions (ISR) in humans ahead of clinical trials.